Meta-Molding Arrays

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$500,000.00
Award Year:
2003
Program:
SBIR
Phase:
Phase I
Contract:
1R43DK062593-01A1
Agency Tracking Number:
DK062593
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
SYNTRIX BIOSYSTEMS, INC.
SYNTRIX BIOSYSTEMS, INC., BOX 166, 16625 REDMOND WAY NE, STE M, REDMOND, WA, 98052
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
JOHN ZEBALA
() -
Business Contact:
JOHN ZEBALA
(425) 867-9692
JZEBALA@EARTHLINK.NET
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Protein chips offer the potential to profile the levels and kinetics of proteins in tissues of the digestive and endocrine systems in a highly multiplexed format. Despite this potential, the majority of protein chips are based on arrayed bio-molecules obtained from biologic or enzymatic sources. Chips that rely on biology or enzymes suffer from several inherent shortcomings that include a restricted bio-molecule repertoire that is time-consuming and costly to manufacture, especially at high-density. We propose to overcome these limitations by developing a Meta-Molding array technology that consists of arrays of novel synthetic antibody mimetics. Mimetics will be identified using a novel and purely chemical discovery paradigm termed PNAdisplay. Consistent with previous studies in the field of dynamic combinatorial chemistry, we hypothesize that PNA-display will permit us to screen large heterodimer populations and identify at least moderate affinity mimetics in a facile system (i. e. < 10 (M). Arrays of such moderate-affinity mimetics employed with an orthogonal analytical method such as MALDI-TOF will provide an analytical capability exceeding that of antibody arrays alone, but without the disadvantages. This SBIR Phase I proposal is designed to prove the feasibility of using PNA-display to identify at least moderate affinity mimetics. Feasibility will set the stage to move into an aggressive Phase II program to develop a Meta-Molding array that monitors global intracellular signaling by detecting specific phosphopeptides. Inappropriate intracellular phosphorylation results in several diseases, including cancer, non-insulin dependent diabetes, and peripheral neuropathies. Syntrix will commercialize the Meta-Molding arrays that result from this research through third-party joint ventures.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government